The promise and the perils of antigen testing
A new UK plan to use antigen tests for wide-scale screening for Covid-19 may not be the easy win the government is seeking.
Glaxo moves up a place in the RSV treatment race
The start of a pivotal trial of Glaxosmithkline’s RSV vaccine adds another late-stage project to the pipeline for this underserved disease category.
Some of biopharma’s biggest assets face a solo existence
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Interest in Tyk2 might soon tick up
Pfizer is still the only big pharma to have followed Bristol's lead in going all-in on the mechanism.
Aducanumab: this time it’s personal
The focus shifts to whether the FDA will overrule its own panel and approve the Alzheimer’s project.
Anti-amyloid approaches come back from the dead
Lilly and Roche bask in the reflected glow of aducanumab's benign briefing documents.
Scanning the horizon for future Covid-19 treatments
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
Amylyx provides hope in amyotrophic lateral sclerosis
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Finding the next Vertex
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
